INTRODUCTION {#sec1-1}
============

Muir-Torre syndrome (MTS) is a rare skin condition with an autosomal dominant inheritance pattern, which is characterized clinically by the coincident occurrence of neoplasms of the sebaceous gland or keratoacanthomas associated with one or more visceral malignancies in the absence of precipitating factors, such as, ulcerative colitis or hepatitis. Sebaceous tumors associated with MTS include sebaceous adenoma and epithelioma, basal cell epithelioma with sebaceous differentiation, and sebaceous carcinoma.\[[@ref22]\] Colorectal and genitourinary carcinomas constitute the most commonly seen visceral tumors in patients with MTS.\[[@ref1][@ref4]\] Patients with MTS exhibit genetic mutations in the human MutS homolog (MSH)-2, MutL homolog (MLH)-1, and MutS homolog (MSH)-6 DNA mismatch repair genes.\[[@ref14]\] Hereditary nonpolyposis colorectal cancer (HNPCC) and familial adenomatous polyposis (FAP) are genetic disorders, which predispose patients to colorectal cancer. When these patients subsequently develop primary brain tumors the condition is termed Turcot\'s Syndrome. We present the case of a 58-year-old male with a known diagnosis of MTS who subsequently developed a glioblastoma multiforme with mutations in MSH2 and MSH6 representing a case of simultaneous MTS and Turcot\'s Syndrome.

CASE REPORT {#sec1-2}
===========

History {#sec2-1}
-------

A 58-year-old male was diagnosed with colon cancer in February 1999, stage T3 N1 M0, which was treated by right hemicolectomy followed by adjuvant chemotherapy with 5-fluorouracil and leucovorin. He had no further recurrence of this tumor. In 2004, the patient started noticing "cysts" on his skin, for which he presented to a dermatologist. Biopsies of the skin lesions were taken. This prompted genetic testing on the patient\'s colonic adenocarcinoma, which revealed a mutation in the MSH2 gene, rendering the patient with a diagnosis of MTS. The patient presented to neurosurgical attention in 2007 with complaints of unsteady gait along with episodes of transient paresthesias involving the left arm, torso, and leg. His immediate family history included a deceased sister with a history of an astrocytoma and deceased mother with colon cancer; genetic testing was not performed on either.

Examination {#sec2-2}
-----------

The patient exhibited no neurologic deficits. Magnetic resonance imaging (MRI) studies revealed the presence of a well-demarcated, right posterior parietal mass roughly 2.2 cm in diameter. The tumor appeared as an isointense signal on the T~1~-weighted image with enhancement after administration of gadolinium contrast \[[Figure 1](#F1){ref-type="fig"}\], and as a hyperintense signal on the T~2~-weighted image. Computed tomography (CT) of the chest, abdomen, and pelvis was negative for masses.

![Preoperative sagittal (a) and axial (b) T1-weighted magnetic resonance images of the brain with gadolinium contrast demonstrate the presence of an enhancing mass in the right posterior parietal region](SNI-4-52-g001){#F1}

Operation/pathology/postoperative course {#sec2-3}
----------------------------------------

Given the patient\'s history and the need to determine whether the brain mass represented a metastatic lesion from his previous colon cancer or a primary brain tumor, the patient initially underwent an MRI-guided, frameless stereotactic biopsy of the enhancing margin of the brain lesion for histologic diagnosis. Pathology revealed scattered atypical glial cells with monosomy of chromosome 7 in some of the cells. A distinct classification was unable to be determined. Therefore, roughly 2 weeks following the biopsy, the patient underwent an image-guided, awake right parietal craniotomy for resection of the tumor. The surgery proceeded without complication and the patient was discharged to home with no new neurological deficits on postoperative day one. The pathological report from this specimen definitively proved the tumor to be a glioblastoma multiforme (World Health Organization \[WHO\] grade 4) with positive immunohistochemical staining for p53 and GFAP and a Ki-67 proliferative index of 25%. Immunostaining for the mismatch repair proteins MSH2, MLH1, and MSH6 revealed that the tumor lacked staining with MSH2 and MSH6 with intact staining for MLH1, suggestive of a germline mutation. Molecular analysis demonstrated a high level of microsatellite instability by detecting evidence of microsatellite instability in 5 of 10 genetic loci used as markers.

DISCUSSION {#sec1-3}
==========

MTS was first described by Muir and Torre in the late 1960s in separate case reports. In Muir, *et al*.\'s study, the patient\'s visceral malignancies included primary carcinomas of the small intestine, colon, and larynx, with concomitant facial keratoacanthomata.\[[@ref16]\] Torre described an individual who had cancer of the ampulla of Vater along with numerous sebaceous tumors (e.g., sebaceous adenomas).\[[@ref23]\]

Lynch, *et al*. initially discussed the concept of MTS representing a clinical variant of HNPCC when the authors observed sebaceous gland neoplasms among their study population of families affected by colon cancer.\[[@ref11]\] Further studies demonstrated genetic mutations common to both, including mutations in the MSH2, MLH1, and MSH6 DNA mismatch repair genes, resulting in deficient DNA mismatch-repair proteins, and, in turn, microsatellite instability.\[[@ref2][@ref3][@ref5][@ref7][@ref8][@ref10][@ref12]--[@ref14][@ref15][@ref18][@ref19]\] Of note, the proportion of mutations involving MSH2 and MLH1 is almost equal in HNPCC, while in MTS, mutations in the MSH2 gene is implicated in the overwhelming majority of time.\[[@ref9][@ref14]\] Microsatellite-stable neoplasms, however, do occur in patients with MTS, prompting researchers to postulate that a second variant of MTS exists, with its genetic basis potentially involving other gene sequences or promoter hypermethylation.\[[@ref20][@ref21]\]

The development of brain tumors in patients with colon cancer associated with the inherited conditions of either HNPCC or FAP is termed Turcot\'s syndrome. Similar to MTS, Turcot\'s syndrome type 1 is a clinical variant of HNPCC and specifically entails those individuals who develop brain neoplasms.\[[@ref6]\] To our knowledge, our case represents the second published report of a brain neoplasm occurring in a patient previously diagnosed with MTS, and thus only the second documented case of a patient with concomitant diagnoses of MTS and Turcot\'s syndrome. Okamoto, *et al*.\[[@ref17]\] described a 49-year-old male with a history of colon cancer and sebaceous adenoma who presented with a right frontal lobe mass and underwent a partial frontal lobectomy with subtotal tumor resection. After histologic examination and molecular analysis, the lesion was revealed to be consistent with an astrocytoma (WHO Grade 3) with microsatellite instability and mutation of the p53 gene.\[[@ref17]\] Further molecular testing for mutations in the MSH2, MLH1, or MSH6 DNA mismatch repair genes was not performed in the previous study.

CONCLUSIONS {#sec1-4}
===========

By demonstrating a mutation in the MSH2 and MSH6 mismatch repair genes from the tumor specimen, we present the first case in which genotypic changes consistent with HNPCC has been conclusively documented in a patient who has, what may be best categorized as an overlap syndrome of Muir-Torre and Turcot\'s syndromes.
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